OGEN Stock Overview A development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Oragenics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Oragenics Historical stock prices Current Share Price US$0.36 52 Week High US$7.74 52 Week Low US$0.25 Beta 0.45 1 Month Change 29.64% 3 Month Change -22.78% 1 Year Change -93.27% 3 Year Change -98.75% 5 Year Change -98.87% Change since IPO -100.00%
Recent News & Updates Oragenics, Inc. has filed a Follow-on Equity Offering. Dec 20
Oragenics, Inc. has filed a Follow-on Equity Offering in the amount of $10 million. Oct 12
Oragenics, Inc. Plans to Initiate Phase II Clinical Trials Oct 10
Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002 Oct 08 Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $4.453593 million. Sep 06
Oragenics, Inc. has filed a Follow-on Equity Offering in the amount of $4.453593 million. See more updates Oragenics, Inc. has filed a Follow-on Equity Offering. Dec 20
Oragenics, Inc. has filed a Follow-on Equity Offering in the amount of $10 million. Oct 12
Oragenics, Inc. Plans to Initiate Phase II Clinical Trials Oct 10
Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002 Oct 08 Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $4.453593 million. Sep 06
Oragenics, Inc. has filed a Follow-on Equity Offering in the amount of $4.453593 million.
Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients Aug 21 Oragenics, Inc. has filed a Follow-on Equity Offering.
Oragenics, Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range Aug 15
New major risk - Financial position Aug 11
First half 2024 earnings released: US$1.21 loss per share (vs US$2.92 loss in 1H 2023) Aug 11
Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing Aug 09
Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients Jul 10 Oragenics, Inc. has completed a Follow-on Equity Offering. Jun 27
Oragenics, Inc. has filed a Follow-on Equity Offering. Jun 25
Oragenics Announces NYSE American Acceptance of Plan of Compliance Jun 20
Oragenics, Inc. Appoints William “Frank” Peacock MD as Chief Clinical Officer May 23
Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial May 18
First quarter 2024 earnings released: US$0.70 loss per share (vs US$1.41 loss in 1Q 2023) May 17
Full year 2023 earnings released: US$9.18 loss per share (vs US$7.11 loss in FY 2022) Apr 01
Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion Mar 20
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion Mar 05 Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $2.1 million. Feb 29
Oragenics, Inc. has filed a Follow-on Equity Offering. Oragenics, Inc. Announces Leadership Transition
Oragenics, Inc. Prepares for Phase II Clinical Trials to Treat Concussion Feb 05
New major risk - Share price stability Jan 31 Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $5 million. Jan 24
Oragenics, Inc. has filed a Follow-on Equity Offering. Jan 16
Oragenics, Inc. (NYSEAM:OGEN) completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc. Dec 30
Third quarter 2023 earnings released: US$0.85 loss per share (vs US$1.99 loss in 3Q 2022) Nov 12
Oragenics, Inc., Annual General Meeting, Dec 14, 2023 Oct 31
Oragenics Announces Directorate Appointments Oct 19 Oragenics, Inc. (NYSEAM:OGEN) entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc. Oct 06
Second quarter 2023 earnings released: US$1.51 loss per share (vs US$1.85 loss in 2Q 2022) Aug 13 Oragenics, Inc. announced that it has received $0.85 million in funding Aug 09
Oragenics, Inc. Announces the Award of Grant from CQDM for the Collaborative Development of a Variant-Agnostic COVID-19 Protein Subunit Vaccine Candidate Jun 07
Insufficient new directors Jun 01
Oragenics, Inc. Regains Compliance with NYSE American Feb 04
Oragenics, Inc. Reports Favorable Toxicology Results for Its Covid-19 Intranasal Vaccine Candidate Dec 23
Oragenics, Inc. Receives NYSE American Notice Regarding Compliance with Section 1003(f)(v) Dec 22
Oragenics, Inc. Announces Board Changes Dec 20 Oragenics, Inc. Appoints Kimberly Murphy as Secretary and Treasurer
Oragenics, Inc. Announces Resignation of Michael Sullivan as Chief Financial Officer, Effective from December 14, 2022 Nov 17
Price target increased to US$2.25 Nov 16
Oragenics, Inc., Annual General Meeting, Dec 16, 2022 Oct 01
Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate Aug 25
Price target increased to US$2.25 Aug 18 Oragenics, Inc. Appoints Kimberly M. Murphy as Chief Executive Officer
Oragenics Announces Publication of Positive Data for Its NT-Cov2-1 Intranasal Covid-19 Vaccine Candidate in Scientific Reports Jun 15
Price target decreased to US$2.25 Apr 27
Executive Chairman recently bought US$66k worth of stock Apr 02
Price target decreased to US$2.25 Mar 29 Shareholder Returns OGEN US Biotechs US Market 7D 1.6% -3.8% -2.7% 1Y -93.3% -2.6% 23.4%
See full shareholder returns
Return vs Industry: OGEN underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: OGEN underperformed the US Market which returned 23.4% over the past year.
Price Volatility Is OGEN's price volatile compared to industry and market? OGEN volatility OGEN Average Weekly Movement 13.6% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.9% 10% least volatile stocks in US Market 3.2%
Stable Share Price: OGEN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: OGEN's weekly volatility has decreased from 23% to 14% over the past year, but is still higher than 75% of US stocks.
About the Company Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics.
Show more Oragenics, Inc. Fundamentals Summary How do Oragenics's earnings and revenue compare to its market cap? OGEN fundamental statistics Market cap US$4.34m Earnings (TTM ) -US$19.97m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) OGEN income statement (TTM ) Revenue US$0 Cost of Revenue US$13.49m Gross Profit -US$13.49m Other Expenses US$6.48m Earnings -US$19.97m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.63 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio 16.9%
How did OGEN perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 20:11 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Oragenics, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Edward Woo Ascendiant Capital Markets LLC Theodore O'Neill Ascendiant Capital Markets LLC Keith Markey Griffin Securities
Show 3 more analysts 
